Detlef Schuppan

Summary

Publications

  1. doi request reprint Anti-fibrotic therapy: lost in translation?
    Detlef Schuppan
    Division of Molecular and Translational Medicine, Dept of Medicine I, University of Mainz Medical School, Mainz, Germany
    J Hepatol 56:S66-74. 2012
  2. doi request reprint Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
    Detlef Schuppan
    Molecular and Translational Medicine, University Medical Center, Johannes Gutenberg University, Mainz, Germany
    J Gastroenterol Hepatol 28:68-76. 2013
  3. pmc Evolving therapies for liver fibrosis
    Detlef Schuppan
    Institute of Molecular and Translational Medicine and Department of Medicine I, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
    J Clin Invest 123:1887-901. 2013
  4. doi request reprint Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP
    Jörn M Schattenberg
    Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
    Am J Physiol Gastrointest Liver Physiol 303:G498-506. 2012
  5. doi request reprint Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic
    Jörn M Schattenberg
    Department of Medicine I bCenter for Molecular and Translational Medicine, University Medical Center of the Johannes Gutenberg University, Langenbeckstrase 1, Mainz, Germany
    Curr Opin Lipidol 22:479-88. 2011

Collaborators

  • Tim Zimmermann
  • Jörn M Schattenberg
  • Marcus Schuchmann
  • Marcus A Wörns
  • Arno Schad
  • Michael Nagel
  • You Wen He
  • Thomas Longerich
  • Peter R Galle
  • Tobias Kohl
  • Yong Ook Kim

Detail Information

Publications5

  1. doi request reprint Anti-fibrotic therapy: lost in translation?
    Detlef Schuppan
    Division of Molecular and Translational Medicine, Dept of Medicine I, University of Mainz Medical School, Mainz, Germany
    J Hepatol 56:S66-74. 2012
    ..Moreover, upcoming novel biomarkers and imaging technologies will soon permit a more exact and efficient assessment of fibrosis progression and regression...
  2. doi request reprint Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
    Detlef Schuppan
    Molecular and Translational Medicine, University Medical Center, Johannes Gutenberg University, Mainz, Germany
    J Gastroenterol Hepatol 28:68-76. 2013
    ..Here, we highlight the aspects of NAFLD epidemiology and pathophysiology that are beginning to lead to novel pharmacological approaches to address this growing health-care challenge...
  3. pmc Evolving therapies for liver fibrosis
    Detlef Schuppan
    Institute of Molecular and Translational Medicine and Department of Medicine I, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
    J Clin Invest 123:1887-901. 2013
    ..We also touch upon relevant clinical study endpoints, optimal study design, and developments in fibrosis imaging and biomarkers...
  4. doi request reprint Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP
    Jörn M Schattenberg
    Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
    Am J Physiol Gastrointest Liver Physiol 303:G498-506. 2012
    ..Thus predisposition to liver injury involving increased hepatocellular apoptosis is a critical mediator of accelerated fibrogenesis, and prevention of liver injury will be a most important measure for patients with chronic liver disease...
  5. doi request reprint Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic
    Jörn M Schattenberg
    Department of Medicine I bCenter for Molecular and Translational Medicine, University Medical Center of the Johannes Gutenberg University, Langenbeckstrase 1, Mainz, Germany
    Curr Opin Lipidol 22:479-88. 2011
    ....